Mereo BioPharma (MREO) Notes Payables (2017 - 2024)

Mereo BioPharma (MREO) reported Notes Payables of $5.5 million for Q4 2024, little changed quarter-over-quarter from $5.6 million in Q3 2024.

Mereo BioPharma (MREO) Notes Payables (2017 - 2024) Analysis & Trends

Mereo BioPharma (MREO) has 5 years of Notes Payables data on file, last reported at $5.5 million in Q4 2024.

Notes Payables for Q4 2024 came in at $5.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $5.5 million (changed N/A YoY), and the FY2024 annual result was $5.5 million, changed N/A from the prior year.
Notes Payables steadied at $5.5 million in Q4 2024 per MREO's latest filing, from $5.6 million in the prior quarter.
Over five years, Notes Payables peaked at $13.0 million in Q4 2022 and troughed at $4.6 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Mereo BioPharma	252.49 Mn	252.49 Mn	-

Download Data